KalVista Pharmaceuticals (KalVista Pharmaceuticals) EPS (Diluted) : $-3.15 (TTM As of Jan. 2024)

KalVista Pharmaceuticals EPS (Diluted) Chart

KalVista Pharmaceuticals Annual Data
	Trend	Dec14	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
EPS (Diluted)		Get a 7-Day Free Trial					-1.38	-1.64	-2.42	-3.36	-3.33

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EPS (Diluted)	Get a 7-Day Free Trial															-0.75	-0.77	-0.74	-0.80	-0.84

Competitive Comparison of KalVista Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, KalVista Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's PE Ratio falls into.

KalVista Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

KalVista Pharmaceuticals's Diluted EPS for the fiscal year that ended in Apr. 2023 is calculated as

KalVista Pharmaceuticals's Diluted EPS for the quarter that ended in Jan. 2024 is calculated as

EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals  (NAS:KALV) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

KalVista Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (KalVista Pharmaceuticals) Business Description